Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.44 USD
-0.07 (-4.64%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.46 +0.02 (1.39%) 7:22 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 1 - 20 ( 108 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Allo, Bringing New Potluck Dishes to the II CART
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
IND Cleared for ADI-270 in r/r RCC; First Look in 1H:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Deep Dive: Turning the Tide From Oncology to Autoimmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Phase 1 Trial of ADI-001 in Lupus Nephritis to Initiate This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EHA 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2024: ADI-270 Showing High Target Sensitivity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Phase 1 GLEAN Study Continues to Enroll MCL Patients; ADI-001 Expanding into Autoimmune Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; ADI-001 and ADI-270 Remain on Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Following Raise; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Clinical Pipeline and Corporate Outlook Conference Call
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E